Breaking News, Collaborations & Alliances

Novozymes, ThioLogics In Conjugation Platform Pact

To offer serum-stable drug-albumin conjugation capability

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novozymes Biopharma has partnered with ThioLogics to offer serum-stable drug-albumin conjugation capabilities. The collaboration combines Novozymes’ modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics’ site-specific maleimide conjugation platform, allowing Novozymes to offer serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.    “Combining the benefits of Novozymes’ and ThioLogics’ technology...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters